Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;15(3):770-778.
doi: 10.1002/1878-0261.12808. Epub 2020 Oct 15.

Vaccination against HPV: boosting coverage and tackling misinformation

Affiliations
Review

Vaccination against HPV: boosting coverage and tackling misinformation

Janne Bigaard et al. Mol Oncol. 2021 Mar.

Abstract

The availability of human papillomavirus (HPV) vaccines and screening tests has raised the possibility of globally eliminating cervical cancer, which is caused by HPV. Cervical cancer is a very common malignancy worldwide, especially among deprived women. High vaccination coverage is key to the containment and eventual elimination of the infection. Public HPV vaccination programmes in Italy and Denmark were swiftly established and are among the most successful worldwide. Still, in both countries, it has been challenging to achieve and maintain the recommended coverage of > 80% in girls. In a well-studied Italian region, vaccination coverage in girls at age 15 years (World Health Organization's gold standard) reached 76% in 2015 but decreased to 69% in 2018, likely due to work overload in public immunization centres. In Denmark, doubts about safety and efficacy of the HPV vaccine generated a decline in coverage among girls age 12-17, from 80% in 2013 down to 37% in 2015, when remedial actions made it rise again. Insights from these two countries are shared to illustrate the importance of monitoring coverage in a digital vaccine registry and promptly reacting to misinformation about vaccination.

Keywords: HPV; cervical cancer; coverage; misinformation; social media; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
HPV coverage estimates available for 75 member states (Figure reproduced from UNICEF/WHO [13]).
Fig. 2
Fig. 2
Number of girls and boys aged 11–18 receiving ≥ 1 dose each year, FVG Region, North‐Eastern Italy, 2008–2018 (Figure modified from [8]).
Fig. 3
Fig. 3
Number of young women aged 12–17 who initiate HPV vaccination per month, June 2012 to December 2017 (Figure reproduced from Statens Serum Institut [30]).

Similar articles

Cited by

References

    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2007) Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 90, 1–636. - PMC - PubMed
    1. de Martel C, Plummer M, Vignat J & Franceschi S (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141, 664–670. - PMC - PubMed
    1. World Health organization (2014) Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 89, 465–491. - PubMed
    1. Bruni L, Diaz M, Barrionuevo‐Rosas L, Herrero R, Bray F, Bosch FX, de Sanjose S & Castellsague X (2016) Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 4, e453–e463. - PubMed
    1. Nguyen‐Huu NH, Thilly N, Derrough T, Sdona E, Claudot F, Pulcini C & Agrinier N (2020) Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine 38, 1315–1331. - PubMed

Publication types

MeSH terms

Substances